医学
贾纳斯激酶
真性红细胞增多症
鲁索利替尼
骨髓增生性疾病
内科学
癌症研究
肿瘤科
药理学
骨髓纤维化
骨髓
细胞因子
作者
Anthony M. Hunter,Prithviraj Bose
标识
DOI:10.1080/14656566.2024.2385729
摘要
Introduction The hallmark discovery of hyperactivation of the janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway was a sentinel moment in the history of myeloproliferative neoplasms (MPNs). This finding paved the way for the development of JAK inhibitors, which now represent the foundation of myelofibrosis therapy. With four JAK inhibitors now approved for myelofibrosis, awareness of their clinical efficacy and safety data and recognition of their unique pharmacologic attributes are of critical importance. Additionally, ruxolitinib represents an integral part of the therapeutic arsenal for polycythemia vera.
科研通智能强力驱动
Strongly Powered by AbleSci AI